Interaction Checker

Ubrogepant etkileşimleri

Ubrogepant (Ubrelvy) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 80 belgelenmiş etkileşim var: 65 majör, 8 orta, 7 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (65)

  • AmiodaronantiaritmikMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • AprepitantCYP3A4 inhibitörüMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • ArmodafinilMSS uyarıcısıMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • BosentanCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Darunavir ve kobisistatantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Deferasiroksdemir takviyesiMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • DronedaronantiaritmikMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • EfavirenzantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Efavirenz, lamivudin ve tenofovirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Eritromisinmakrolid antibiyotikMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • EslikarbazepinantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • FenitoinantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • FosamprenavirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • FosaprepitantCYP3A4 inhibitörüMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • FosfenitoinantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • GriseofulvinantifungalMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • İtrakonazolazol antifungalMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • İvakaftorCYP3A4 inhibitörüMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • İzoniazidantibiyotikMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • KarbamazepinantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Klaritromisinmakrolid antibiyotikMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • KlobazambenzodiazepinMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Lopinavir ve ritonavirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • LorlatinibCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Mirabegronbeta adrenerjik agonistMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • MitapivatCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • NevirapinantiretroviralMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • OkskarbazepinantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • PalbosiklibCYP3A4 inhibitörüMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • PerampanelantikonvülsanMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Posakonazolazol antifungalMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • PrimidonantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • RifabutinantibiyotikMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • SenobamatantikonvülsanMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • SiklosporinimmünosüpresanMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • SimetidinH2 blokeriMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Suvoreksantsedatif-hipnotikMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • SuzetrijinCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • TopiramatantikonvülsanMajör

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

  • Vorikonazolazol antifungalMajör

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (8)

  • Dekstrometorfan ve kinidinserotonerjik ilaçOrta

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • EltrombopagOATP1B1 inhibitörüOrta

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • FluvoksaminSSRIOrta

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • GreyfurtYiyecek ve içecekOrta

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • Karvedilolbeta blokerOrta

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • KinidinantiaritmikOrta

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • SiprofloksasinflorokinolonOrta

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (Ubrogepant etiketi, İlaç etkileşimleri)

  • Zerdeçal (kurkumin)Bitkisel ürün ve takviyeOrta

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (Ubrogepant etiketi, İlaç etkileşimleri)

Minör değinmeler (7)

  • Butalbital ve parasetamolbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Butalbital, aspirin ve kafeinbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Butalbital, aspirin, kafein ve kodeinbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Butalbital, parasetamol ve kafeinbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Butalbital, parasetamol, kafein ve kodeinbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

  • Fenobarbital, hiyosiyamin, atropin ve skopolaminbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

  • MetoheksitalbarbitüratMinör

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (Ubrogepant etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Ubrogepant ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.